Drug intelligence / Profile preview

Abz-722

Development stage: Preclinical
Lead developer: Abzyme Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

Abz-722 is a bispecific T-cell engager (BiTE) developed by Abzyme Therapeutics LLC. It functions as an inhibitor of Programmed cell death protein 1 (PD-1). This drug is currently in preclinical development for the treatment of neoplasms, aiming to harness the immune system to target cancer cells by blocking the PD-1 pathway.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on Abz-722.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abz-722.

Explore the full profile